Preview

Merck Acquisition of Medco

Powerful Essays
Open Document
Open Document
3075 Words
Grammar
Grammar
Plagiarism
Plagiarism
Writing
Writing
Score
Score
Merck Acquisition of Medco
Merck Acquisition of Medco
Case Study
John X
Devry University – Keller Graduate School of Management

Finance 561
Professor
May 22, 2011
Table of Contents
Abstract………………………………………………………………………………………p.g. 3
Company backgrounds……………………………………………………….………………p.g. 3 Merck & Co., Inc. ………………………………………..…………………….…....p.g. 3 Medco Containment Services Inc. ............................……..…………………………p.g. 4
Reasons for Mergers…………………………………………………………………………p.g. 5
Economies of Scale…………………………………………………………………..p.g. 5

Market Share…………………………………………………………………………p.g. 6

Synergy………………………………………………………………………………p.g. 6

Eliminate competition…………………………………………….……….………....p.g. 6

Increase depth and diversity of product line………………………….…….……….p.g. 7

Keeping opportunities from competitors……………………………….……………p.g. 7
Merger Areas of Caution………………………………………………………….….………p.g. 7 Technology Integration……………………………………………………..………..p.g. 8 Culture Shock…………………………………………………………….…..………p.g. 8
Consolidated Financials………………………………………………………………..…….p.g. 9 Consolidated Combined Statement of Income……………………………………….p.g. 9 Consolidated Combined Balance Sheet and Owners Equity……………………p.g. 10, 11
Summary Discussion…………………………………………………………….…………p.g. 11 Recommendation……………………………………………………………..…….p.g. 12
References……………………………………………………………….……………..p.g. 14, 15

Abstract Mergers are done for many reasons. Merck & Co., Inc.’s , Merck, consideration of a merger or acquisition of Medco Containment Services Inc., Medco, will need to be based on several factors and need to be in the best interest of Merck’s stockholders. This assessment will go over the reasons mergers occur and how Medco will achieve this reason or not and if so if it is reasonable enough to offer an offer comparable to Medco’s Chief Financial Officers request of $6.6 billion dollars. Reasons to be evaluated are economies of scale, market share, synergy, elimination of competition, increasing depth and diversity of product line, and keeping opportunities



References: Merck Settles FTC Charges that Its Acquisition of Medco Could Cause Higher Prices and Reduced Quality for Prescription Drugs (Merck, 1998); http://www.ftc.gov/opa/1998/08/merck.shtm Published August 27, 1998; Retrieved May 19, 2011 Merck to spin-off Merck-Medco (Merck, 2002); by John George http://www.bizjournals.com/philadelphia/stories/2002/01/28/daily15.html Published January 29, 2002; Retrieved May 19, 2011 Merger as Marriage: Communication Issues in Post – Merger Integration (Merger); by Kevin J Retrieved May 19, 2011 Successful Post-Merger Integration: Realizing the Synergies (Synergies); by Bohlin, Dale, and Retrieved May 19, 2011 Reasons why Mergers and Acquisitions Can Fail (Reasons); by Freda Turner http://www.bizjournals.com/jacksonville/stories/2000/08/28/smallb2.html Published August 28, 2011; Retrieved May 20, 2011 Retrieved May 20, 2011 Merck & Co., Inc http://www.referenceforbusiness.com/history2/23/Merck-Co-Inc.html Retrieved May 21, 2011 Retrieved May 21, 2011 Information Technology and Post Merger Integration (Info); by Gopal Sondur www.infosys.com/finacle/finacle-connect/Issue_08/.../feature.doc Retrieved May 21, 2011

You May Also Find These Documents Helpful

  • Satisfactory Essays

    Recently this year, Abbott laboratories an international healthcare company will obtain possession of St. Jude Medical in an agreement that is valued at $25 billion. This contract between the two companies is considered the largest, by combining and increasing their business with doctors and hospitals. More and more companies are merging with one another to obtain access to the latest technologies, as well as reducing their overall costs. Since recently, St. Jude Medical's shares have been drastically dropping, this merger with Abbott will not only increase their business but, it will also improve the end result of patient's lives. According to USA Today, after the announcement was release publicly, St. Jude Medical's shares went up 25.6% rising to $77.79 a share. Although, Abbott's stock decline 7.8% to $40.42. Abbott also has plans to take over St. Jude Medical's debt of $5.7 billion. They viewed this new investment as an opportunity to introduce new medical products beyond the cardiovascular field globally. With this new merger, they project that by 2020 the combine companies will bring in sales and profits in a $500 million pretax increase.…

    • 306 Words
    • 2 Pages
    Satisfactory Essays
  • Satisfactory Essays

    Fi561 You Decide

    • 430 Words
    • 2 Pages

    This is my concern; I want to make sure that Merck pays a premium for Medco at $6.6 billion dollars. The combination of…

    • 430 Words
    • 2 Pages
    Satisfactory Essays
  • Satisfactory Essays

    In today’s uncertain economic and regulatory environment for the health services industry, many organizations may be presented with merger and acquisition opportunities to gain market share and drive financial and operational efficiencies. Given the current state of this market segment:…

    • 336 Words
    • 1 Page
    Satisfactory Essays
  • Better Essays

    When two or more companies are combined, they form a merger. This is an effective corporate strategy. All the capabilities of companies forming the mergers are combined to serve as a unique motivation for the venture. Other motivational factors for them are to acquire greater market share and enhance competition. In order to improve a business’s performance, mergers are typically formed.…

    • 999 Words
    • 3 Pages
    Better Essays
  • Powerful Essays

    The Medicines Company

    • 868 Words
    • 5 Pages

    The Medicines Company Case Write-Up: Terence Cho, Felipe Duarte, Aleks Loiko, Robert Shaw, and James Wang…

    • 868 Words
    • 5 Pages
    Powerful Essays
  • Satisfactory Essays

    Euro takeover

    • 474 Words
    • 2 Pages

    • Bidders (Raider, LBO, W.K.) ( , , ) – What is your walkway price, i.e. highest price willing to pay? • Banks – Credit rating, interest rate – Lending limit & Structure Credit Analysis • Evaluate post‐merger credit worthiness – Statutory vs. subsidiary merger – Post merger cash flow • How much synergy to include? How much synergy to include? – Post merger debt level 2 Capital Structure • Senior Debt – – – – Term loans & Revolving credit…

    • 474 Words
    • 2 Pages
    Satisfactory Essays
  • Best Essays

    The manufacturer like Merck-Medco, Lilly-PCS were concerned about losing access to their industries to PBM. PBMs are companies that administer drug benefit programs for employers and health insurance carriers. Their contracts are directly to managed care organizations, self-insured employers, insurance companies, Medicare, and almost all Federal and State government health benefits plans. To make the benefit plan more affordable PBM lowered their claims processing fees and also offered rebate retention. PBM also processed prescription drug claims, reviewed prescriptions, offered generic and branded medicines through mail services as well. Hence, due to PBM’s efficiency of delivering and processing the drug cut overall cost of health care benefits, the manufacturer industry got a big hit in their business. So, in the early 1990S, a large growth of managed care changed the health care industry that also had a heavy impact on…

    • 2738 Words
    • 11 Pages
    Best Essays
  • Satisfactory Essays

    Some of the key factors that drive mergers between two healthcare organizations are patient services, financial balances. In the case study, PRMC shows high operating cost for low budget which lead them to financial loss for several years (Buchbinder & Shank, 2012). BRM has smaller facilities, more patients are not likely to get full patient services and PRMC is a little bigger, so that means more patients are likely to get most of its patient services. The merging will cause both of these hospitals to provide the best quality care for patients causing less angry patients and law suit.…

    • 255 Words
    • 2 Pages
    Satisfactory Essays
  • Good Essays

    Sherman’s situation was complicated by the fact that she had a third party, Promedico corporation, which also claimed the services of her and her team. The lack of a plan for the merger and lack of transparency as to how the company would ultimately be reorganized negatively affected the initial success of this merger. Nguyen and Kleiner (2003) found that merger success is directly correlated to the level and quality of planning involved. Furthermore, most merger failures occur in the integration phase, due to lack of communication or lack of a clear vision (p. 447). In this case, Glaxo-Wellcome owed its employees a clear plan as to how they would be reorganized and what their role would be in the new…

    • 833 Words
    • 4 Pages
    Good Essays
  • Satisfactory Essays

    Hospital Mergers

    • 202 Words
    • 1 Page

    Hospital mergers have proven to improve productivity and efficiency in three different ways. First, mergers reduce non-price competition which results in extensive duplication of services which in turn leads to higher cost. Second, there is an increased patient base which could lead to greater utilization rates, increased marginal utility of labor, and enhanced revenues. Last, administrative cost should decrease due to consolidation of services. Thus, a positive correlation is present between mergers and cost. Mergers tend to be in close geographic proximity, leading to a concern regarding the increased market power. They generate cost savings that encourage the merged firm to lower prices as well as an increased market concentration.…

    • 202 Words
    • 1 Page
    Satisfactory Essays
  • Better Essays

    Merck & Co

    • 1066 Words
    • 5 Pages

    Merck had a 14% increase in sales between 1997 and 1998 and 22% increase in sales from 1998 – 1999, and a 13% annual increase in earnings over the same period. Merck’s business strategy consists of two parts: (1) developing and marketing new drugs through internal research, and (2) developing partnerships with smaller biotechnology companies. Since 1995, Merck had launched 15 new products that earned $5.9 billion on sales of $32.7 billion. Furthermore, Merck may agree to license new drugs from other firms and with its larger capital and greater assets, can assume the risk of submitting the drug through various regulatory approval phases. If the drug becomes profitable, Merck can earn significant cash flows while paying a royalty to the licensor. However, most important is the option that Merck has in deciding when to abandon or continue on this project (deferability or optionality). If Merck reaches a point when its expected NPV is negative, it can simply abandon the project.…

    • 1066 Words
    • 5 Pages
    Better Essays
  • Best Essays

    Ho, V., & Hamilton, B. H. (2000). Hospital Mergers and Acquisitions: Does Market Consolidation Harm Patients?. Journal of Health Economics, 19(5). P. 767-791.…

    • 3777 Words
    • 13 Pages
    Best Essays
  • Satisfactory Essays

    Brahma vs Antarctica

    • 829 Words
    • 4 Pages

    When considering the merger several aspects have to be taken into account. Table 1 provides an…

    • 829 Words
    • 4 Pages
    Satisfactory Essays
  • Good Essays

    Merck Case

    • 587 Words
    • 4 Pages

    This should be maintained for this deal as well. Hence the most Merck could pay as licensing fee is = 37.84%…

    • 587 Words
    • 4 Pages
    Good Essays
  • Good Essays

    Azn and Merck

    • 584 Words
    • 3 Pages

    The all-cash deal for MedImmune, worth $58 a share, appears to be the largest purchase ever of an American biotechnology company. The $58 a share AstraZeneca will pay represents a 21 percent premium over MedImmune’s closing price on Friday and is 53 percent higher than MedImmune’s closing price the day before it announced that it would put itself on the block. For AstraZeneca, based in London, the acquisition would help bolster its product pipeline after some recent setbacks, and would supplement its portfolio with biologic drugs — protein-based therapies that are made in cultures of living cells. There is another motive, too: because biotechnology protein drugs are far more complex than typical pills, which are simple chemicals, they have been largely insulated from the generic competition that can wipe out sales of a blockbuster drug almost overnight. The deal will also move AstraZeneca into vaccines. AstraZeneca said the deal would add to its cash earnings per share, excluding amortization, by 2009 and that it could achieve $500 million a year in cost savings.…

    • 584 Words
    • 3 Pages
    Good Essays